CERN-MEDICIS is a spin-off dedicated to R&D in life sciences and medical applications that will produce innovative medical radioisotopes.
Using a technology developed at ISOLDE – the Isotope Mass Separator Online facility at CERN – radioisotopes for medical research are produced using a 1.4 GeV proton beam.
On December 13, CERN-MEDECIS produced the first batch of radioisotopes, in particular Terbium-155, a gamma emitter that is considered a promising radioisotope for diagnosing prostate cancer. The first sample of terbium-155 produced by CERN-MEDICIS was sent to the radiopharmaceutical sciences group at C2TN, to be studied under the project “MEDICIS-produced radioisotope beams for medicine” (Medicis-Promed). This project is part of the “Ação Marie Curie ITN” led by CERN and involves the C2TN researchers António Paulo and António Pereira Gonçalves, who supervise PhD students Alice d’Onofrio and Sanjib Chowdhury, respectively.